Abstract
We report on a 38-year-old patient who presented with rapidly progressive interstitial lung disease (ILD), without any signs of muscular involvement. Antinuclear antibody testing by indirect immunofluorescence revealed a nuclear titer of 1:320 with a fine speckled and a cytoplasmic titer of 1:1’280 with a fine speckled pattern. Subsequent myositis-specific and myositis-associated antibody tests with commercial multiplex dot-immunoassays showed a strong positive result for anti-Ha antibodies, also confirmed by protein immunoprecipitation, establishing the diagnosis of anti-synthetase syndrome with associated ILD. Despite initial improvement after treatment with intravenous cyclophosphamide and high dose steroids, he relapsed shortly after, with additional muscular symptoms. Subsequent escalation of therapy with rituximab resulted in sustained remission. Considering the scarcity of data about the clinical presentation and prognosis of patients with anti-Ha antibodies, our report provides additional information on diagnostic challenges and therapeutic response in these patients.
| Original language | English |
|---|---|
| Article number | 1750916 |
| Journal | Frontiers in Immunology |
| Volume | 17 |
| Early online date | 27 Feb 2026 |
| DOIs | |
| Publication status | Published - 27 Feb 2026 |
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Keywords
- anti-Ha
- anti-synthetase syndrome
- case report
- cyclophosphamide
- diagnostic test
- interstitial lung disease
- myositis
- rituximab
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Fingerprint
Dive into the research topics of 'Anti-Ha anti-synthetase syndrome presenting as rapidly progressive interstitial lung disease: a case report of high confidence autoantibody testing'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS